Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors

被引:52
作者
Boivin, G
Goyette, N
机构
[1] CHU Laval, CHUQ, Res Ctr Infect Dis, Quebec City, PQ G1V 4G2, Canada
[2] Univ Laval, Dept Med Biol, Quebec City, PQ, Canada
关键词
influenza B; inhibitors; virus; influenza A;
D O I
10.1016/S0166-3542(01)00219-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Forty-two influenza A and 23 influenza B isolates collected from untreated subjects during the 1999-2000 influenza season in Canada were tested for their susceptibility to three neuraminidase inhibitors (zanamivir, oseltamivir carboxylate and RWJ-270201 or BCX-1812) using a chemiluminescent neuraminidase assay. Influenza B isolates were less susceptible than A viruses to all tested drugs. RWJ-270201 was the most potent drug against both influenza A(H3N2) (mean IC50: 0.60 nM) and B (mean IC50: 0.87 nM) viruses. Oseltamivir carboxylate was more active than zanamivir for influenza A(H3N2) isolates (mean IC50: 0.73 vs. 2.09 nM) whereas it was less potent against B viruses (mean IC50): 11.53 vs. 4.15 nM). (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:143 / 147
页数:5
相关论文
共 15 条
[1]   Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir [J].
Bantia, S ;
Parker, CD ;
Ananth, SL ;
Horn, LL ;
Andries, K ;
Chand, P ;
Kotian, PL ;
Dehghani, A ;
El-Kattan, Y ;
Lin, T ;
Hutchison, TL ;
Montgomery, JA ;
Kellog, DL ;
Babu, YS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1162-1167
[2]   Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies [J].
Barnett, JM ;
Cadman, A ;
Gor, D ;
Dempsey, M ;
Walters, M ;
Candlin, A ;
Tisdale, M ;
Morley, PJ ;
Owens, IJ ;
Fenton, RJ ;
Lewis, AP ;
Claas, ECJ ;
Rimmelzwaan, GF ;
De Groot, R ;
Osterhaus, ADME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :78-87
[3]   Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults [J].
Boivin, G ;
Goyette, N ;
Hardy, I ;
Aoki, F ;
Wagner, A ;
Trottier, S .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04) :1471-1474
[4]   Evaluation of a rapid optical immunoassay for influenza viruses (FLU OIA test) in comparison with cell culture and reverse transcription-PCR [J].
Boivin, G ;
Hardy, I ;
Kress, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (02) :730-732
[5]   Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir [J].
Buxton, RC ;
Edwards, B ;
Juo, RR ;
Voyta, JC ;
Tisdale, M ;
Bethell, RC .
ANALYTICAL BIOCHEMISTRY, 2000, 280 (02) :291-300
[6]   Drug therapy: Prevention and treatment of influenza. [J].
Couch, RB .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (24) :1778-1787
[7]   Influenza virus neuraminidase inhibitors [J].
Gubareva, LV ;
Kaiser, L ;
Hayden, FG .
LANCET, 2000, 355 (9206) :827-835
[8]  
GUBAREVA LV, 1999, 2 INT S INFL OTH RES
[9]   Inhaled zanamivir for the prevention of influenza in families. [J].
Hayden, FG ;
Gubareva, LV ;
Monto, AS ;
Klein, TC ;
Elliott, MJ ;
Hammond, JM ;
Sharp, SJ ;
Ossi, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (18) :1282-1289
[10]   Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections [J].
Hayden, FG ;
Osterhaus, ADME ;
Treanor, JJ ;
Fleming, DM ;
Aoki, FY ;
Nicholson, KG ;
Bohnen, AM ;
Hirst, HM ;
Keene, O ;
Wightman, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) :874-880